We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+2.48%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$891M
AUM Growth
+$7.78M
Cap. Flow
+$63.7M
Cap. Flow %
7.14%
Top 10 Hldgs %
87.29%
Holding
26
New
3
Increased
3
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$64.8M
2
IVVD icon
Invivyd
IVVD
+$23.5M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$14.5M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.86M
5
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$1.16M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.3M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$16.2M
3
REPL icon
Replimune Group
REPL
+$3.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.45%
2 Financials 0.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$280M 31.46%
28,212,376
– –
REPL icon
2
Replimune Group
REPL
$814M
$145M 16.28%
4,896,074
-112,171
-2% -$3.64M
KRON
3
DELISTED
Kronos Bio
KRON
$80M 8.98%
3,818,283
– –
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$74.5M 8.36%
1,315,952
-451,398
-26% -$27.3M
IMGO
5
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$60.5M 6.78%
+3,018,737
New +$64.8M
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$41.7M 4.68%
3,320,608
– –
IMA
7
ImageneBio Inc
IMA
$63.1M
$28.4M 3.18%
187,427
– –
IVVD icon
8
Invivyd
IVVD
$180M
$26.7M 3%
+632,855
New +$23.5M
ALPN
9
DELISTED
Alpine Immune Sciences Inc
ALPN
$21.7M 2.43%
2,029,580
+744,680
+58% +$6.86M
SANA icon
10
Sana Biotechnology
SANA
$885M
$19M 2.13%
843,750
– –
IMUX icon
11
Immunic
IMUX
$182M
$15.8M 1.78%
178,816
– –
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.42B
$14.9M 1.67%
623,836
– –
SPRB
13
Spruce Biosciences
SPRB
$119M
$13M 1.46%
28,814
– –
PRTK
14
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$12.7M 1.42%
2,606,809
+6,399
+0.2% +$35.3K
ICVX
15
DELISTED
Icosavax, Inc. Common Stock
ICVX
$12.6M 1.42%
+426,395
New +$14.5M
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.2M 1.26%
251,271
+23,788
+10% +$1.16M
AVIR icon
17
Atea Pharmaceuticals
AVIR
$379M
$5.77M 0.65%
164,577
-582,291
-78% -$16.2M
CMPI
18
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$5.3M 0.59%
1,335,050
– –
OMEG
19
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.88M 0.55%
501,000
– –
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
$4.49M 0.5%
100,262
– –
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.11M 0.35%
999,364
– –
EPIX
22
DELISTED
ESSA Pharma
EPIX
$2.63M 0.29%
328,196
– –
JNCE
23
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.05M 0.23%
275,513
– –
IMCR icon
24
Immunocore
IMCR
$1.78B
$1.91M 0.21%
51,535
– –
TRVI icon
25
Trevi Therapeutics
TRVI
$2.49B
$1.77M 0.2%
1,263,408
– –
1
2

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2021 Portfolio in Review

As of Q3 2021, Omega Fund Management held 26 positions worth $891M, up 0.88% from $884M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Omega Fund Management deployed $63.7M of net new capital in Q3 2021, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Imago BioSciences, Inc. Common stock: 3,018,737 shares worth $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $27.3M trimmed.

  • Omega Fund Management's largest Q3 2021 buy was Imago BioSciences, Inc. Common stock: 3,018,737 shares worth $60.5M.
  • Omega Fund Management added most to Alpine Immune Sciences Inc in Q3 2021, an estimated $6.86M increase.
  • Omega Fund Management's biggest Q3 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $27.3M.
  • Omega Fund Management's ten largest holdings make up 87% of its $891M portfolio in Q3 2021.
  • Omega Fund Management opened 3 new positions and closed 0 in Q3 2021.
  • Omega Fund Management's portfolio value rose 0.88% quarter-over-quarter to $891M.

Based on Omega Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.